Dynamiclear is a TGA Listed Medicine.A Search for the Registration of Dynamiclear can be done through the Therapeutics Goods Administration (TGA) Government website. Available in a pdf download.
The TGA is respected as being one of the most strict and difficult regulatory organizations in the world. Being a TGA Listed Medicine means that Dynamiclear has been thoroughly reviewed by Government Health Authorities and has been assessed for safety, quality control and efficacy.
The Food and Drug Administration (FDA) in the United States and the Medicines and Healthcare products Regulatory Agency (MRHA) in the UK and other health authorities around the world recognize TGA Registration.
You can read the requirements for obtaining approval on the TGA Government website.
Dynamiclear is manufactured in a Pharmaceutical GMP Certified Laboratory. In addition to Dynamiclear being registered as a TGA listed medicine it is also manufactured in a Pharmaceutical Good Manufacturing Practice (GMP) compliant laboratory that is independently inspected for Sanitary, Quality Control and Safety.
GMP Certification is a strict health code that is recognized by health industries in the United States, Canada, Australia, Japan, the UK, Europe and other countries. The application of GMP standards guarantees the quality, hygiene and consistency of all of the batches that Dynamiclear produce.
The Ingredients in Dynamiclear are Certified to be Gentle and Non-toxic to healthy skin. The Therapeutic Goods Administration (TGA)of Australia and the European Medicine Ethics Agency approve the active ingredients in Dynamiclear to be safe when used topically on skin infections in adults. Furthermore, the ingredients are manufctured to controlled concentrations in accordance with global standards.
The effectiveness and safety of Dynamiclear is published in the Journal of Drugs and Dermatology. The New York based Journal of Drugs in Dermatology, one of the most credible sources for new medical developments in the field of skin care, published early in 2012 that:
"The Dynamiclear formulation was well tolerated, and efficacy was demonstrated in a number of measured parameters, which are helpful in the symptomatic management of HSV-1 and HSV-2 lesions in adult patients. Remarkably, the effects seen from this product came from a single application."
Download the Journal's full review of the Dynamiclear Clinical Trial (PDF file)
More Information about the Safety & Risks of Dynamiclear